Skip to main content

Table 1 Comparison between the two studied groups according to baseline patient characteristics

From: Intermittent fasting during adjuvant chemotherapy may promote differential stress resistance in breast cancer patients

  Intermittent fasting
(n = 24)
Non-fasting (n = 24) P
Age (years)
 Mean ± SD 43.96 ± 7.37 47.42 ± 11.73 0.229
 Median (min.–max.) 44.0 (30.0–60.0) 45.0 (27.0–66.0)
Weight (kg)    
 Mean ± SD 88.83 ± 14.14 87.83 ± 17.40 0.828
 Median (min.–max.) 86.0 (65.0–113.0) 86.50 (49.0–130.0)
Height (m)
 Mean ± SD 1.67 ± 0.05 1.66 ± 0.05 0.330
 Median (min.–max.) 1.68 (1.55–1.75) 1.66 (1.50–1.72)
BMI (kg/m2)
 Mean ± SD 31.77 ± 4.06 31.89 ± 5.35 0.933
 Median (min.–max.) 32.23 (23.88–36.96) 32.33 (21.67–43.94)
ER No. % No. % MCp = 0.462
 Negative 6 (25.0%) 4 (16.7%)
 1 +  0 (0.0%) 1 (4.2%)
 2 +  8 (33.3%) 5 (20.8%)
 3 +  10 (41.7%) 14 (58.3%)
PR
 Negative 7 (29.2%) 4 (16.7%) MCp = 0.595
 1 +  3 (12.5%) 3 (12.5%)
 2 +  3 (12.5%) 6 (25.0%)
 3 +  11 (45.8%) 11 (45.8%)
Grade
 I 0 (0.0%) 4 (16.7%) MCp = 0.141
 II 18 (75.0%) 16 (66.7%)
 III 6 (25.0%) 4 (16.7%)
Stage    
 IA 4 (16.7%) 6 (25.0%) MCp = 0.236
 IIA 12 (50.0%) 5 (20.8%)
 IIB 2 (8.3%) 4 (16.7%)
 IIIA 1 (4.2%) 4 (16.7%)
 IIIC 5 (20.8%) 5 (20.8%)
  1. SD standard deviation, BMI body mass index, ER estrogen receptor, PR progesterone receptor, MC Monte Carlo
  2. P P-value for comparing between intermittent fasting and non-fasting
  3. *Statistically significant at P < 0.05